Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.20.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Current assets    
Cash $ 399,891 $ 681,759
Prepaid expenses 7,476 9,054
Total current assets 407,367 690,813
Total Assets 407,367 690,813
Current liabilities    
Accounts payable 166,643 213,880
Accrued expenses 373,012 419,836
Accrued interest payable 179,528 674,041
Related party payables 193,868 905,443
Derivative liabilities 61,350 60,650
Common stock subscriptions payable 100,126 79,624
Preferred stock subscriptions payable 1,022,000 1,000,000
Notes payable - current - related parties * Includes unamortized debt discount related to detached warrants of none and $8,656 at March 31, 2020 and December 31, 2019, respectively 81,810 760,886
Notes payable - current - non-related parties 104,183 169,574
Total current liabilities 2,282,520 4,283,934
Total Liabilities 2,282,520 4,283,934
Stockholders' Deficit    
Common stock, $0.00001 par value; 800,000,000 shares authorized; 262,091,617 and 214,626,540 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively 2,619 2,146
Additional paid-in capital 18,136,680 15,969,311
Accumulated deficit (19,961,191) (19,511,168)
Total Transbiotec, Inc. stockholders' deficit (1,821,892) (3,539,711)
Noncontrolling interest (53,261) (53,410)
Total Stockholders' Deficit (1,875,153) (3,593,121)
Total Liabilities and Stockholders' Deficit 407,367 690,813
Series A Convertible Preferred stock [Member]    
Stockholders' Deficit    
Series A-1 Convertible Preferred stock, $0.00001 par value; 2,000,000 shares authorized, no shares issued and outstanding as of March 31, 2020 and December 31, 2019